Published in J Hepatol on October 01, 2005
Impact of immunosuppressant therapy on early recurrence of hepatocellular carcinoma after liver transplantation. Clin Mol Hepatol (2014) 0.76
Fourth Forum on Liver Transplantation Hepatocellular carcinoma: where are the controversies? J Hepatol (2005) 0.75
Effect of surgical margin status on survival and site of recurrence after hepatic resection for colorectal metastases. Ann Surg (2005) 4.86
Budd-Chiari syndrome: a review by an expert panel. J Hepatol (2003) 3.69
Rates and patterns of recurrence following curative intent surgery for colorectal liver metastasis: an international multi-institutional analysis of 1669 patients. Ann Surg (2009) 3.15
Hepatic resection for noncolorectal nonendocrine liver metastases: analysis of 1,452 patients and development of a prognostic model. Ann Surg (2006) 2.70
Relationship between steatosis, inflammation, and fibrosis in chronic hepatitis C: a meta-analysis of individual patient data. Gastroenterology (2006) 2.26
Intrahepatic cholangiocarcinoma: an international multi-institutional analysis of prognostic factors and lymph node assessment. J Clin Oncol (2011) 2.13
The impact of waiting list alpha-fetoprotein changes on the outcome of liver transplant for hepatocellular carcinoma. J Hepatol (2011) 2.12
Non-alcoholic fatty liver disease in liver transplant recipients: another story of "seed and soil". Am J Gastroenterol (2009) 1.83
Polyfunctional HCV-specific T-cell responses are associated with effective control of HCV replication. Eur J Immunol (2008) 1.70
A survival analysis of the liver-first reversed management of advanced simultaneous colorectal liver metastases: a LiverMetSurvey-based study. Ann Surg (2012) 1.69
Improved long-term outcome of surgery for advanced colorectal liver metastases: reasons and implications for management on the basis of a severity score. Ann Surg Oncol (2007) 1.60
Complications of elective liver resections in a center with low mortality: a simple score to predict morbidity. Arch Surg (2011) 1.57
Erythromycin intravenous bolus infusion in acute upper gastrointestinal bleeding: a randomized, controlled, double-blind trial. Gastroenterology (2002) 1.57
Potential impact of in situ liver splitting on the number of available grafts. Transplantation (2002) 1.55
Risk of complications after abdominal paracentesis in cirrhotic patients: a prospective study. Clin Gastroenterol Hepatol (2009) 1.52
OncoSurge: a strategy for improving resectability with curative intent in metastatic colorectal cancer. J Clin Oncol (2005) 1.52
Performance of endosonography-guided fine needle aspiration and biopsy in the diagnosis of pancreatic cystic lesions. Am J Gastroenterol (2003) 1.51
Infection and rejection in liver transplant patients: a 10-year Swiss single-centre experience. Swiss Med Wkly (2005) 1.48
Sinusoidal obstruction syndrome and nodular regenerative hyperplasia are frequent oxaliplatin-associated liver lesions and partially prevented by bevacizumab in patients with hepatic colorectal metastasis. Histopathology (2010) 1.48
Repeat curative intent liver surgery is safe and effective for recurrent colorectal liver metastasis: results from an international multi-institutional analysis. J Gastrointest Surg (2009) 1.41
The role of hepatic ischemia-reperfusion injury and liver parenchymal quality on cancer recurrence. Dig Dis Sci (2014) 1.39
Risk factors for early and late biliary complications in pediatric liver transplantation. Pediatr Transplant (2014) 1.38
Conditional survival after surgical resection of colorectal liver metastasis: an international multi-institutional analysis of 949 patients. J Am Coll Surg (2010) 1.37
Surgery versus intra-arterial therapy for neuroendocrine liver metastasis: a multicenter international analysis. Ann Surg Oncol (2011) 1.31
Comparison between hepatic wedge resection and anatomic resection for colorectal liver metastases. J Gastrointest Surg (2006) 1.22
A simple score for predicting alcohol relapse after liver transplantation: results from 387 patients over 15 years. Arch Intern Med (2007) 1.21
The impact of portal vein resection on outcomes for hilar cholangiocarcinoma: a multi-institutional analysis of 305 cases. Cancer (2012) 1.16
'Liver first' approach in the treatment of colorectal cancer with synchronous liver metastases. Dig Surg (2009) 1.16
Surgical management of patients with synchronous colorectal liver metastasis: a multicenter international analysis. J Am Coll Surg (2013) 1.14
Long term results after complete or incomplete surgical resection of liver hydatid disease. Swiss Med Wkly (2003) 1.14
IgG4-associated cholangitis: a comparative histological and immunophenotypic study with primary sclerosing cholangitis on liver biopsy material. Mod Pathol (2009) 1.11
A nomogram to predict long-term survival after resection for intrahepatic cholangiocarcinoma: an Eastern and Western experience. JAMA Surg (2014) 1.11
Granulocyte-colony stimulating factor induces proliferation of hepatic progenitors in alcoholic steatohepatitis: a randomized trial. Hepatology (2008) 1.10
A model for dropout assessment of candidates with or without hepatocellular carcinoma on a common liver transplant waiting list. Hepatology (2012) 1.08
Management of hepatocellular adenoma: solitary-uncomplicated, multiple and ruptured tumors. World J Gastroenterol (2005) 1.06
Interleukin-1 receptor antagonist modulates the early phase of liver regeneration after partial hepatectomy in mice. PLoS One (2011) 1.05
Surgical management of early-stage hepatocellular carcinoma: resection or transplantation? J Gastrointest Surg (2008) 1.04
Neoadjuvant chemotherapy in patients with stage IV colorectal cancer: a comparison of histological response in liver metastases, primary tumors, and regional lymph nodes. Ann Surg Oncol (2010) 1.03
Surgical management and long-term outcome of complicated liver hydatid cysts caused by Echinococcus granulosus. Surgery (2005) 0.97
Liver resection for colorectal metastases after chemotherapy: impact of chemotherapy-related liver injuries, pathological tumor response, and micrometastases on long-term survival. Ann Surg (2013) 0.97
A 3-month course of long-acting repeatable octreotide (sandostatin LAR) improves portal hypertension in patients with cirrhosis: a randomized controlled study. Am J Gastroenterol (2007) 0.97
Orthotopic liver transplantation in rats. J Vis Exp (2012) 0.96
Recurrence after operative management of intrahepatic cholangiocarcinoma. Surgery (2013) 0.96
Biliary atresia: Swiss national study, 1994-2004. J Pediatr Gastroenterol Nutr (2008) 0.96
Liver transplantation for Budd-Chiari syndrome: A European study on 248 patients from 51 centres. J Hepatol (2005) 0.96
Early liver biopsy, intraparenchymal cholestasis, and prognosis in patients with alcoholic steatohepatitis. BMC Gastroenterol (2011) 0.95
The place of downstaging for hepatocellular carcinoma. J Hepatol (2010) 0.95
Gene expression profiling provides insights into pathways of oxaliplatin-related sinusoidal obstruction syndrome in humans. Mol Cancer Ther (2011) 0.95
Radiofrequency ablation of small liver malignancies under magnetic resonance guidance: progress in targeting and preliminary observations with temperature monitoring. Eur Radiol (2009) 0.95
Management of a ruptured hydatid cyst involving the ribs: Dealing with a challenging case and review of the literature. Int J Surg Case Rep (2012) 0.94
Monitoring of cytomegalovirus infection in solid-organ transplant recipients by an ultrasensitive plasma PCR assay. J Clin Microbiol (2003) 0.93
An unusual, presumably hepatic mass. Lancet (2002) 0.93
Long-term renal function after liver transplantation is related to calcineurin inhibitors blood levels. Clin Transplant (2006) 0.93
Percutaneous treatment of liver tumors with an adapted probe for cooled-tip, impedance-controlled radio-frequency ablation under open-magnet MR guidance: initial results. Eur Radiol (2003) 0.92
Sinusoidal obstruction syndrome is a major feature of hepatic lesions associated with oxaliplatin neoadjuvant chemotherapy for liver colorectal metastases. J Am Coll Surg (2006) 0.90
Pharmacokinetics, efficacy, and safety of mycophenolate mofetil in combination with standard-dose or reduced-dose tacrolimus in liver transplant recipients. Liver Transpl (2009) 0.89
Hepatocellular carcinoma in a liver-cell adenoma within a non-cirrhotic liver. Eur J Gastroenterol Hepatol (2006) 0.88
Tumor size predicts vascular invasion and histologic grade among patients undergoing resection of intrahepatic cholangiocarcinoma. J Gastrointest Surg (2014) 0.88
Adjuvant radio-chemotherapy for extrahepatic biliary tract cancers. BMC Cancer (2011) 0.87
Cure of multifocal panhepatic hepatoblastoma: is liver transplantation always necessary? J Pediatr Surg (2010) 0.87
Humoral and cellular rejection after combined liver-kidney transplantation in low immunologic risk recipients. Transpl Int (2008) 0.87
Histamine H1 blocker hydroxyzine improves sleep in patients with cirrhosis and minimal hepatic encephalopathy: a randomized controlled pilot trial. Am J Gastroenterol (2007) 0.86
Conversion to sirolimus-based immunosuppression in maintenance liver transplantation patients. Liver Transpl (2007) 0.85
Survival after lung metastasectomy in colorectal cancer patients with previously resected liver metastases. World J Surg (2012) 0.85
Factors predicting survival after post-transplant hepatocellular carcinoma recurrence. J Hepatobiliary Pancreat Sci (2013) 0.85
Emergency liver transplantation in amodiaquine-induced fulminant hepatitis. Am J Trop Med Hyg (2007) 0.85
Treatment of fulminant liver failure by transplantation of microencapsulated primary or immortalized xenogeneic hepatocytes. Xenotransplantation (2005) 0.85
The impact of wait list body mass index changes on the outcome after liver transplantation. Transpl Int (2012) 0.85
Systematic review and meta-analysis of fibrin sealants for patients undergoing pancreatic resection. HPB (Oxford) (2013) 0.85
Image-guided multipolar radiofrequency ablation of liver tumours: initial clinical results. Eur Radiol (2007) 0.85
Blunt abdominal trauma: does the use of a second-generation sonographic contrast agent help to detect solid organ injuries? AJR Am J Roentgenol (2004) 0.85
Partial hepatectomy versus radiofrequency ablation for hepatocellular carcinoma: confirming the trial that will never be, and some comments on the indications for liver resection. Hepatology (2010) 0.84
Hepatic regeneration is decreased in a rat model of sinusoidal obstruction syndrome. J Surg Oncol (2009) 0.84
Lack of evidence for ribavirin-induced bone loss. Hepatology (2002) 0.84
Tolerability of everolimus-based immunosuppression in maintenance liver transplant recipients. Clin Transplant (2010) 0.84
Is Hepatic Resection for Large or Multifocal Intrahepatic Cholangiocarcinoma Justified? Results from a Multi-Institutional Collaboration. Ann Surg Oncol (2014) 0.84
Validation of a dropout assessment model of candidates with/without hepatocellular carcinoma on a common liver transplant waiting list. Transpl Int (2014) 0.82
Prostaglandin E(1) protects human liver sinusoidal endothelial cell from apoptosis induced by hypoxia reoxygenation. Microvasc Res (2002) 0.82
Management of hepatocellular carcinoma in the waiting list before liver transplantation. J Hepatol (2005) 0.82
Hyperimmune anti-HBs plasma as alternative to commercial immunoglobulins for prevention of HBV recurrence after liver transplantation. BMC Gastroenterol (2010) 0.82
Hepatocellular adenoma and polycystic ovary syndrome. Liver Int (2003) 0.82
Persistence of mild parkinsonism 4 months after liver transplantation in patients with preoperative minimal hepatic encephalopathy: a study on neuroradiological and blood manganese changes. Transpl Int (2002) 0.81
Predicting survival after pulmonary metastasectomy for colorectal cancer: previous liver metastases matter. BMC Surg (2010) 0.81
Integrating sorafenib into an algorithm for the management of post-transplant hepatocellular carcinoma recurrence. J Hepatol (2013) 0.81
Microchimerism after liver transplantation: absence of rejection without abrogation of anti-donor cytotoxic T-lymphocyte-mediated alloreactivity. Liver Transpl (2005) 0.81
Management of hepatocellular carcinoma on the waiting list before liver transplantation: time for controlled trials? Liver Transpl (2007) 0.81
Comparative performances of staging systems for early hepatocellular carcinoma. HPB (Oxford) (2009) 0.81